评估多组分干预管理中重度慢性肾脏病患者肾脏结局:肾脏结局预防与评估策略(SKOPE)随机对照试验方案
SKOPE 是一项为期3年的随机对照试验,在新加坡5家政府补贴的综合诊所纳入896例40至80岁中重度慢性肾脏病(CKD)患者,评估由护士健康教练、医师算法化管理培训、SGLT2i药物补贴和定期病例讨论组成的多组分干预(MCI)对肾脏结局的作用。主要结局为随机化至36个月最终随访的估算肾小球滤过率(eGFR)总斜率。
要点
- 多组分干预包括护士健康教练、医师算法化管理培训、SGLT2i补贴和定期CKD病例讨论。
- 研究对象为新加坡5家政府补贴综合诊所中40至80岁中重度CKD患者,共896例。
- 主要结局为随机化至36个月最终随访的eGFR总斜率。
核心结论
- 若SKOPE被证实有效、成本效益好且可接受,应考虑在全国范围及类似区域医疗系统中推广。
研究设计与样本
- 本研究为为期3年的随机对照试验,纳入新加坡5家政府补贴综合诊所中896例40至80岁中重度CKD患者。
主要发现
- 多组分干预包括护士/服务协调员接受健康教练培训以进行动机性对话和CKD特异性饮食运动生活方式咨询,采用面对面、电话和安全视频会议混合随访方式。
- 多组分干预包括培训医师进行基于算法的CKD标准化管理。
- 多组分干预包括对CKD患者使用SGLT2i药物给予补贴。
- 多组分干预包括定期CKD病例讨论会。
- 主要结局为随机化至36个月最终随访的eGFR总斜率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic kidney disease (CKD) poses a global health challenge with high morbidity and mortality rates. Early detection and prompt intervention are critical in preventing progression to end-stage kidney disease (ESKD) and cardiovascular complications. Effective CKD management requires comprehensive care packages that integrate both pharmacological and non-pharmacological interventions within collaborative, team-based models, aiming to enhance patient outcomes and overall quality of life. The goal of the Strategies for Kidney Outcomes Prevention and Evaluation (SKOPE) study is to establish effective multicomponent intervention (MCI) strategies for evaluating and preventing kidney outcomes in patients with moderate to advanced CKD within primary care settings in Singapore. METHODS: This study is a 3-year randomized controlled trial among 896 participants aged between 40 and 80 years with moderate or advanced CKD in five government-subsidized polyclinics in Singapore. The components of the MCI are (1) nurses/service coordinators trained as health coaches for motivational conversation and CKD-specific lifestyle counseling on diet and exercise, using a hybrid follow-up approach of in-person, telephone, and secure video meetings; (2) training physicians in algorithm-based standardized management of CKD; (3) subsidy on SGLT2i medications for CKD; and (4) regular CKD case review meetings. The primary outcome is the estimated glomerular filtration rate (eGFR) total slope from randomization to final follow-up at 36 months. DISCUSSION: If shown to be effective, cost-effective, and acceptable, SKOPE should be considered for scaling country-wide and in similar regional healthcare systems. TRIAL REGISTRATION: ClinicalTrials.gov NCT05295368. Registered on March 25, 2022.
引用
- Jafar TH, Tan NC, Gandhi M, et al. Evaluating a multicomponent intervention for managing kidney outcomes among patients with moderate or advanced chronic kidney disease (CKD): protocol for the Strategies for Kidney Outcomes Prevention and Evaluation (SKOPE) randomized controlled trial. Trials. 2024. PMID: 39472975. doi:10.1186/s13063-024-08564-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。